Latest GenomeDx Biosciences Stories
Decipher is the first genomic test for postoperative prostate cancer to gain Medicare coverage SAN DIEGO, Jan.
First study to show that the genomic signature of prostate cancer can predict rapid development of metastatic disease in men who were managed conservatively after surgery SAN DIEGO, Dec.
Builds on initial collaboration with Mayo Clinic that led to the development and commercialization of Decipher in patients following prostate surgery SAN DIEGO, Nov.
SAN DIEGO, Oct.
SAN DIEGO, Sept. 25, 2014 /PRNewswire/ -- GenomeDx Biosciences today announced that it has entered into a contractual agreement with MultiPlan, Inc. for diagnostic laboratory testing.
Oral presentation at American Society for Radiation Oncology Annual Meeting describes Decipher's ability to identify high-risk prostate cancer patients that may benefit from radiation therapy after
Data presented at American Society for Radiology (ASTRO) Annual Meeting in San Francisco SAN FRANCISCO, Sept.
SAN DIEGO, June 16, 2014 /PRNewswire/ -- GenomeDx Biosciences today announced that it has entered into a contractual agreement as a participating provider with Prime Health Services to provide
Two Studies Presented at 2014 AUA Annual Meeting SAN DIEGO, May 20, 2014 /PRNewswire/ -- GenomeDx Biosciences today announced the presentation of data showing that its Decipher®
SAN DIEGO, May 16, 2014 /PRNewswire/ -- GenomeDx Biosciences today announced the launch of the Decipher® Portal Professional, a mobile app designed for iPad tablets that allows registered medical
- A poem in which the author retracts something said in an earlier poem.